Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis.

IF 2.5 3区医学 Q3 ONCOLOGY

World Journal of Surgical Oncology Pub Date : 2025-07-16 DOI:10.1186/s12957-025-03949-1

Jichao Zhu, Jiliang Zhang, Chao Gu

{"title":"Prognostic and clinicopathological value of soluble programmed cell death ligand-1 (sPD-L1) in patients with colorectal cancer: a meta-analysis.","authors":"Jichao Zhu, Jiliang Zhang, Chao Gu","doi":"10.1186/s12957-025-03949-1","DOIUrl":null,"url":null,"abstract":"Background: The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.Methods: We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.Results: Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52-3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.Conclusions: Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"283"},"PeriodicalIF":2.5000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12265264/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03949-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The effect of soluble programmed cell death 1 ligand 1 (sPD-L1) on the prognosis of colorectal cancer (CRC) has been extensively explored; however, the results remain controversial. Therefore, we performed a meta-analysis to determine its exact function in predicting CRC prognosis.

Methods: We retrieved relevant data from the Web of Science, PubMed, Embase, and Cochrane Library databases from their inception to February 24, 2025. We computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) to estimate the value of sPD-L1 in predicting overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) in CRC.

Results: Six studies involving a total of 773 patients were included. The integrated results revealed that higher sPD-L1 levels were significantly associated with unfavorable OS (HR = 2.19, 95%CI = 1.16‒4.15; p = 0.016) and DFS/PFS (HR = 3.14, 95%CI = 1.88‒5.24; p < 0.001) in CRC. However, sPD-L1 was not markedly associated with sex (OR = 1.28, 95%CI = 0.52-3.14; p = 0.596), T stage (OR = 0.65, 95%CI = 0.33‒1.28; p = 0.210), TNM stage (OR = 0.99, 95%CI = 0.57‒1.74; p = 0.976) and lymph node metastasis (OR = 0.86, 95%CI = 0.46‒1.58; p = 0.620) in CRC.

Conclusions: Elevated sPD-L1 levels could serve as a critical factor in predicting both unfavorable OS and DFS/PFS in patients with CRC.

Abstract Image

查看原文本刊更多论文

可溶性程序性细胞死亡配体-1 （sPD-L1）在结直肠癌患者中的预后和临床病理学价值：一项荟萃分析

背景：可溶性程序性细胞死亡1配体1 （sPD-L1）对结直肠癌（CRC）预后的影响已被广泛探讨；然而，研究结果仍然存在争议。因此，我们进行了一项荟萃分析，以确定其在预测CRC预后中的确切功能。方法：我们从Web of Science、PubMed、Embase和Cochrane Library数据库中检索从建立到2025年2月24日的相关数据。我们计算了联合风险比（HRs）和95%置信区间（CIs）来估计sPD-L1在预测结直肠癌总生存期（OS）、无病生存期（DFS）和无进展生存期（PFS）中的价值。结果：6项研究共纳入773例患者。综合结果显示，较高的sPD-L1水平与不良OS显著相关(HR = 2.19, 95%CI = 1.16-4.15；p = 0.016)和DFS / PFS (HR = 3.14, 95% ci = 1.88 - -5.24;结论：sPD-L1水平升高可作为预测结直肠癌患者不良OS和DFS/PFS的关键因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Surgical Oncology ONCOLOGY-SURGERY

CiteScore

4.70

自引率

15.60%

发文量

362

审稿时长

3 months

期刊介绍： World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics. Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.